MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Cleveland BioLabs Company Profile (NASDAQ:CBLI)

Consensus Ratings for Cleveland BioLabs (NASDAQ:CBLI) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Cleveland BioLabs (NASDAQ:CBLI)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for Cleveland BioLabs (NASDAQ:CBLI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/10/2016        
5/16/2016Q116($0.06)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/22/2016Q4($0.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.31)$415.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/12/2015Q215($1.12)$562.10 million$329.90 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2015Q115($1.14)$1.33 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q114($1.02)$3.87 million$1.39 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.09)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014($0.05)($0.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/11/2014Q413($0.12)($0.01)$1.74 million$3.87 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q313($0.14)($0.09)$1.61 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/13/2013Q2 2013($0.16)($0.07)$1.48 million$1.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2013Q1 2013($0.17)($0.22)$1.73 million$1.37 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/8/2012Q312($0.02)($0.30)$23.87 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Cleveland BioLabs (NASDAQ:CBLI)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Cleveland BioLabs (NASDAQ:CBLI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Cleveland BioLabs (NASDAQ:CBLI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
2/25/2015Randy S SaluckDirectorBuy1,891$3.42$6,467.22View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Paul E DicorletoDirectorBuy6,210$1.61$9,998.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Randy S SaluckDirectorBuy3,500$1.60$5,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2013James AntalDirectorBuy3,700$1.56$5,772.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2012James AntalDirectorBuy2,316$2.60$6,021.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Cleveland BioLabs (NASDAQ:CBLI)
DateHeadline
06/22/16 07:51 AMServices Sector Daily Watch: Winners & Losers
05/17/16 11:26 AMCleveland BioLabs, Inc. :CBLI-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/16/16 01:01 PMFriday Morning’s Top Movers – UNIS, HTGM, ORMP, NVDA, CETX, CBLI, RUN - The company is -10.59 pct year-to-date, and -45.64 pct during the past four quarters. Cleveland BioLabs Inc (CBLI) traded at $2.31 + 0.2066 (9.84 pct) on 890 total stock volume. The company is -33.91 pct year-to-date, and +13.61 pct during the past four ...
05/16/16 07:02 AMCleveland BioLabs Reports First Quarter 2016 Financial Results and Development Progress - [at noodls] - BUFFALO, NY--(Marketwired - May 16, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2016. Cleveland BioLabs ...
05/12/16 01:40 PM22nd Century to begin cannabis research at new medical campus labs -
05/06/16 04:55 PMCLEVELAND BIOLABS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit -
04/15/16 02:05 PMCLEVELAND BIOLABS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
04/04/16 06:37 AMCleveland BioLabs Announces Webcast of Annual Meeting - [at noodls] - BUFFALO, NY--(Marketwired - Apr 4, 2016) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that the Company will webcast its 2016 Annual Meeting of Stockholders on April 14, 2016 at its headquarters ...
03/17/16 01:04 AMGLPG Awaits SAPHIRA Data, VTAE Vaults, CBLI Hits A Snag - CERS closed Wednesday' trading at $5.79, down 3.34%. It looks like the progress of regulatory review of Cleveland BioLabs Inc.'s (CBLI) pre-Emergency Use Authorization submission for Entolimod as a radiation countermeasure is going to be delayed.
03/16/16 01:50 PMCLEVELAND BIOLABS INC Files SEC form 8-K, Other Events -
03/16/16 01:00 PMCleveland BioLabs Provides Update on Pre-EUA Review of Entolimod as Radiation Countermeasure - [Marketwired] - Cleveland BioLabs, Inc. today announced an update on the regulatory review of its pre-Emergency Use Authorization submission for entolimod as a radiation countermeasure following the receipt of minutes ...
03/08/16 10:42 AMHottest Services Stocks Now – CAI NEWT INST MOBL - Instructure Inc (INST): INST stock is down 0.47% today. Mobileiron Inc (MOBL): MOBL stock is up 1.98% today. Cleveland Biolabs (CBLI): CBLI stock is down 0.85% today. Weibo Corp (WB): WB stock is up 1.12% today. Care.Com Inc (CRCM): CRCM stock is up 0.78% ...
02/23/16 04:04 PMCLEVELAND BIOLABS INC Files SEC form 10-K, Annual Report -
02/22/16 09:35 AMCLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition -
02/22/16 06:30 AMCleveland BioLabs Reports 2015 Financial Results and Development Progress - [Marketwired] - Cleveland BioLabs, Inc. today reported financial results and development progress for the fourth quarter and year ended December 31, 2015.
02/18/16 05:31 PMCleveland BioLabs, Inc. (CBLI) - Cleveland BioLabs, Inc., a biopharmaceutical company, focuses on developing pharmaceuticals designed to address diseases with unmet medical need. Its lead drug candidate is Entolimod, a Toll-like receptor 5 (TLR5) agonist, which is developing as a ...
02/09/16 09:47 AMHottest Services Stocks Now – ADUS SREV EBIX CBLI - Servicesource International In (SREV): SREV stock is up 4.62% today. Ebix Inc (EBIX): EBIX stock is up 3.77% today. Cleveland Biolabs (CBLI): CBLI stock is up 1.47% today. SP Plus Corporation (SP): SP stock is up 2.71% today. Datawatch Corp (DWCH): DWCH ...
02/09/16 09:47 AMCleveland Biolabs (CBLI) Says Entolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis - Cleveland BioLabs, Inc. (NASDAQ: CBLI) and Roswell Park Cancer Institute (RPCI) today announced the publication of studies elucidating immunotherapeutic mechanisms through which entolimod suppresses metastasis. The data were published in Proceedings of the ...
02/09/16 06:30 AMEntolimod Shown to Suppress Metastasis and Induce Immunity by Stimulating NK-Dendritic-CD8+ T cell Axis in Studies by Cleveland BioLabs and Roswell Park Cancer Institute - [Marketwired] - Cleveland BioLabs, Inc. and Roswell Park Cancer Institute today announced the publication of studies elucidating immunotherapeutic mechanisms through which entolimod suppresses metastasis. The data were ...
02/02/16 07:00 AMCleveland BioLabs Announces Start of Colorectal Cancer Study of Entolimod in Russian Federation - [Marketwired] - Cleveland BioLabs, Inc. today announced the initiation of a Phase 2, single-blind, randomized, placebo-controlled clinical study of the safety and tolerability of entolimod as a neo-adjuvant therapy in ...
01/26/16 06:49 AMCleveland BioLabs Announces Start of Phase 2 Study of CBLB612 in Russian Federation - [at noodls] - BUFFALO, NY--(Marketwired - Jan 26, 2016) - Cleveland BioLabs, Inc. (: ) today announced the start of dosing in a Phase 2, randomized, placebo-controlled clinical study of CBLB612 as myelosuppressive prophylaxis ...
01/22/16 02:25 PMCleveland BioLabs Gets Orphan Status for Entolimod in EU -
01/21/16 06:45 AMCleveland BioLabs Attains Orphan Drug Status From the EMA for Entolimod as a Radiation Countermeasure - [at noodls] - BUFFALO, NY--(Marketwired - Jan 21, 2016) - Cleveland BioLabs, Inc. (: ), today announced that entolimod has been granted orphan drug status by the European Medicines Agency (EMA) for treatment of acute ...
01/21/16 06:30 AM7:30 am Cleveland Biolabs announces that entolimod has been granted orphan drug status by the EMA for treatment of acute radiation syndrome -
12/24/15 12:04 PMCLEVELAND BIOLABS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Material Defin -
12/22/15 06:40 AMCleveland BioLabs and Rusnano Make Additional Investments in Panacela - [at noodls] - BUFFALO, NY--(Marketwired - Dec 22, 2015) - Cleveland BioLabs, Inc. (: ) today announced that through a series of transactions and in cooperation with Open Joint Stock Company RUSNANO (Rusnano) it has ...
12/16/15 12:16 PMCleveland BioLabs, Inc. Earnings Analysis: Q3, 2015 By the Numbers -
12/14/15 06:30 AMEntolimod Shown to Suppress Liver Metastases in Model of Ocular Melanoma in Collaborative Study by Cleveland BioLabs, Emory University and Roswell Park Cancer Institute - [Marketwired] - Cleveland BioLabs, Inc. , Emory University and Roswell Park Cancer Institute today announced the publication of a study in Oncotarget demonstrating the ability of entolimod to suppress liver metastases ...
12/08/15 12:17 PMCLEVELAND BIOLABS INC Financials -
11/30/15 07:00 AMCleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod - [at noodls] - Cleveland BioLabs Announces Expanded U.S. Patent Protection for Entolimod
11/09/15 03:17 PMCLEVELAND BIOLABS INC Files SEC form 10-Q, Quarterly Report -
11/05/15 06:40 AMCleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress - [at noodls] - Cleveland BioLabs Reports Third Quarter 2015 Financial Results and Development Progress
11/05/15 06:31 AMCLEVELAND BIOLABS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh -
11/05/15 06:07 AMQ3 2015 Cleveland Biolabs Inc Earnings Release - Time Not Supplied -
10/27/15 07:15 AMCleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5 - [at noodls] - Cleveland BioLabs to Report Third Quarter 2015 Financial Results on November 5
About Cleveland BioLabs

Cleveland BioLabs logoCleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company's programs are focused developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is entolimod, an immuno-stimulatory agent, which the Company is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. It also has an additional clinical-stage program and multiple projects in different stages of preclinical drug development. Its products include Entolimod, CBLB612, CBL0137 and Mobilan. Entolimod is a toll-like receptor 5 (TLR5). CBLB612 is a compound-based upon a natural activator of another tissue-specific component of the immune system. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CBLI
  • CUSIP:
Key Metrics:
  • Previous Close: $2.57
  • 50 Day Moving Average: $2.29
  • 200 Day Moving Average: $2.95
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $27.69M
  • Current Quarter EPS Consensus Estimate: $-0.16 EPS
Additional Links:
Cleveland BioLabs (NASDAQ:CBLI) Chart for Sunday, June, 26, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha